What’s New in the Management and Treatment of GN: A look at ANCA and LN

Recorded On: 06/21/2022

  • Register
    • Non-member - Free!
    • Member - Free!
    • Subscriber - Free!
    • Free trial - Free!

The complement pathway exerts a central role in the pathophysiology of several glomerular diseases. In lupus nephritis (LN), the complement pathway has been studied for its pathogenic role, its potential as a disease biomarker, and as a therapeutic target. This webinar will briefly approach these aspects and the role of complement research to improve outcomes in lupus nephritis. ANCA will also be a focus of this webinar. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are multisystem disorders resulting in irreversible organ damage. Multiple immune participants contribute to the pathogenesis. The loss of self-tolerance results in the production of ANCA. In humans, therapeutic targeting of C5aR has now demonstrated non-inferiority compared to glucocorticoids and has the potential to be a paradigm changing therapy in AAV. The aim is to personalize management in AAV to improve patient and kidney outcomes.

Juan Mejia-Vilet

Mexico

Vladimir Tesar

Czech Republic

Silke Brix

UK

Key:

Complete
Failed
Available
Locked
ISN-KDIGO Webinar Series on Complement in GN: What’s New in the Management and Treatment of GN: A look at ANCA and LN
Open to view video.
Open to view video.
ISN-KDIGO Webinar Series on Complement in GN: What’s New in the Management and Treatment of GN: A look at ANCA and LN (Japanese)
Open to view video.
Open to view video.
ISN-KDIGO Webinar Series on Complement in GN: What’s New in the Management and Treatment of GN: A look at ANCA and LN (Chinese)
Open to view video.
Open to view video.